Exelixis (EXEL) Revenue (2010 - 2026)
Exelixis (EXEL) recorded quarterly Revenue of $610.8 million in Q2 2026, up 2.03% quarter-over-quarter from $598.7 million in Q1 2026, and up 9.97% on a YoY basis from $555.4 million in Q2 2025.
Exelixis (EXEL) Revenue (2010 - 2026) Analysis & Trends
Exelixis' Revenue history runs 17 years deep, the most recent figure standing at $610.8 million for Q2 2026.
- In Q2 2026, Revenue rose 9.97% year-over-year to $610.8 million; the TTM figure through Apr 2026 stood at $2.4 billion (up 3.33% YoY), while the FY2026 annual figure was $2.3 billion, up 6.98% from the prior year.
- Revenue was $610.8 million for Q2 2026 at Exelixis, up from $598.7 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $637.2 million in Q2 2024 to a low of $356.0 million in Q2 2022.
- Historically, Revenue has averaged $502.4 million across 5 years, with a median of $479.7 million in 2023.
- The sharpest annual moves came in 2024 and 2025: Revenue soared 35.61% in 2024, then retreated 10.82% in 2025.
- A 5-year view of Revenue shows it stood at $423.9 million in 2022, then rose by 13.15% to $479.7 million in 2023, then grew by 12.49% to $539.5 million in 2024, then grew by 10.79% to $597.8 million in 2025, then rose by 2.18% to $610.8 million in 2026.
- The last three Revenue figures came in at $610.8 million (Q2 2026), $598.7 million (Q1 2026), and $597.8 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Exelixis | 13.37 Bn | 12.59 Bn | 590.86 Mn | 610.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 610.81 Mn |
| Jan 2, 2026 | 598.66 Mn |
| Oct 3, 2025 | 597.76 Mn |
| Jul 4, 2025 | 568.26 Mn |
| Apr 4, 2025 | 555.45 Mn |
| Jan 3, 2025 | 566.76 Mn |
| Sep 27, 2024 | 539.54 Mn |
| Jun 28, 2024 | 637.18 Mn |
| Mar 29, 2024 | 425.23 Mn |
| Dec 29, 2023 | 479.65 Mn |
| Sep 29, 2023 | 471.92 Mn |
| Jun 30, 2023 | 469.85 Mn |
| Mar 31, 2023 | 408.79 Mn |
| Dec 30, 2022 | 423.92 Mn |
| Sep 30, 2022 | 411.74 Mn |
| Jul 1, 2022 | 419.43 Mn |
| Apr 1, 2022 | 355.98 Mn |
| Oct 1, 2021 | 328.42 Mn |
| Jul 2, 2021 | 385.18 Mn |
| Apr 2, 2021 | 270.23 Mn |